Category Archives: Stem Cell Treatments

Feb 27 2012

Researchers have isolated egg-producing stem cells from the ovaries of reproductive age women and shown these can produce what appear to be normal egg cells or oocytes, according to a new study.

The discovery "opens the door for development of unprecedented technologies to overcome infertility in women" according to the scientist who led the study.

Jonathan Tilly, of Massachusetts General Hospital in the United States, said: "The primary objective of the current study was to prove that oocyte-producing stem cells do in fact exist in the ovaries of women during reproductive life, which we feel this study demonstrates very clearly."

The researchers developed a precise cell-sorting technique to isolate oocyte producing stem cells (OSCs) without contamination from other cells, according to an article in the March issue of Nature Medicine.

The cells were able, in the laboratory, to form cells spontaneously with characteristic features of oocytes. Further experiments on mice showed such eggs could be fertilised.

Dr Tilly's team is exploring potential clinical applications from its findings which include the establishment of human OSC banks - since these cells, unlike human oocytes, can be frozen and thawed without damage - and the development of mature human oocytes from OSCs for in vitro fertilisation, plus other approaches to improve the outcomes of IVF and other infertility treatments.

In 2004 a report from Dr Tilly's team challenged the fundamental belief, held since the 1950s, that female mammals are born with a finite supply of eggs that is depleted throughout life and exhausted at menopause.

Dr Tilly said: "The discovery of oocyte precursor cells in adult human ovaries, coupled with the fact that these cells share the same characteristic features of their mouse counterparts that produce fully functional eggs, opens the door for development of unprecedented technologies to overcome infertility in women and perhaps even delay the timing of ovarian failure."

Dr Allan Pacey, a fertility expert at the University of Sheffield, told the BBC: "This is a nice study which shows quite convincingly that women's ovaries contain stem cells that can divide and make eggs.

"Not only does this re-write the rule book, it opens up a number of exciting possibilities for preserving the fertility of women undergoing treatment for cancer, or just maybe for women who are suffering infertility by extracting these cells and making her new eggs in the lab."

Read more:
UK & World News: Stem cell boost in fertility study

Researchers have isolated egg-producing stem cells from the ovaries of reproductive age women and shown these can produce what appear to be normal egg cells or oocytes, according to a new study.

The discovery "opens the door for development of unprecedented technologies to overcome infertility in women" according to the scientist who led the study.

Jonathan Tilly, of Massachusetts General Hospital in the United States, said: "The primary objective of the current study was to prove that oocyte-producing stem cells do in fact exist in the ovaries of women during reproductive life, which we feel this study demonstrates very clearly."

The researchers developed a precise cell-sorting technique to isolate oocyte producing stem cells (OSCs) without contamination from other cells, according to an article in the March issue of Nature Medicine.

The cells were able, in the laboratory, to form cells spontaneously with characteristic features of oocytes. Further experiments on mice showed such eggs could be fertilised.

Dr Tilly's team is exploring potential clinical applications from its findings which include the establishment of human OSC banks - since these cells, unlike human oocytes, can be frozen and thawed without damage - and the development of mature human oocytes from OSCs for in vitro fertilisation, plus other approaches to improve the outcomes of IVF and other infertility treatments.

In 2004 a report from Dr Tilly's team challenged the fundamental belief, held since the 1950s, that female mammals are born with a finite supply of eggs that is depleted throughout life and exhausted at menopause.

Dr Tilly said: "The discovery of oocyte precursor cells in adult human ovaries, coupled with the fact that these cells share the same characteristic features of their mouse counterparts that produce fully functional eggs, opens the door for development of unprecedented technologies to overcome infertility in women and perhaps even delay the timing of ovarian failure."

Dr Allan Pacey, a fertility expert at the University of Sheffield, told the BBC: "This is a nice study which shows quite convincingly that women's ovaries contain stem cells that can divide and make eggs.

"Not only does this re-write the rule book, it opens up a number of exciting possibilities for preserving the fertility of women undergoing treatment for cancer, or just maybe for women who are suffering infertility by extracting these cells and making her new eggs in the lab."

View original post here:
Stem cell boost in fertility study

09-11-2011 11:26 Karen Aboody speaks at the 2011 CIRM Grantee Meeting about the developing a stem cell-based clinical trial for malignant brain tumors. Dr. Aboody and her team at the City of Hope Hospital medical center in Duarte, have been funded by CIRM to create a human neural cell line with the ability to target brain tumor cells and deliver a powerful chemotherapeutic agent selectively at tumor sites, effectively destroying invasive glioma cells while sparing normal tissues.

Continued here:
Brain Tumors: Advancing Stem Cell Therapies - 2011 CIRM Grantee Meeting - Video

26-01-2012 02:37 Animacel ltd. is offering your animal stem cell treatment with newly developed stem cell therapy. At the moment, excellent results are with treatments of different joint problems (arthritis and injury/damage of cartilage, hip dysplasia), tendon problems and supporting/adjuvant stem cell therapy for faster healing of broken bones. We are also developing treatment for heart insufficiency, eye dissease, diabetes, etc. See our webpage http://www.animacel.com

See the article here:
Stem cell treatment for animals - Video

WALTHAM, Mass.--(BUSINESS WIRE)--

Histogenics Corporation, a privately held regenerative medicine company, today announced that the Company will present at the 7th Annual New York Stem Cell Summit on February 21st at Bridgewaters New York City. Kirk Andriano, Ph.D., Vice President of Research and Development for Histogenics, will speak about current and future cell therapies being developed by the Company as it works toward commercialization. Lead candidates include NeoCart®, an autologous bioengineered neocartilage grown outside the body using the patient’s own cells for the regeneration of cartilage lesions, and VeriCart™, a three-dimensional cartilage matrix designed to stimulate cartilage repair in a simple, one-step procedure. NeoCart recently entered a Phase 3 clinical trial after reporting positive Phase 2 data, in which all primary endpoints were met and a favorable safety profile was demonstrated.

Dr. Andriano earned his BS in chemistry and biology from Utah State University and his MS and Ph.D. in bioengineering from the University of Utah. Prior to his work at Histogenics, he was the Chief Technology Officer for ProChon Biotech, Ltd. which was acquired by Histogenics in May 2011.

About Histogenics

Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. In May of 2011, Histogenics acquired Israeli cell-therapy company ProChon BioTech. Histogenics’ flagship products focus on the treatment of active patients suffering from articular cartilage derived pain and immobility. The Company takes an interdisciplinary approach to engineering neocartilage that looks, acts and lasts like hyaline cartilage. It is developing new treatments for sports injuries and other orthopaedic conditions, where demand is growing for long-term alternatives to joint replacement. Histogenics has successfully completed Phase 1 and Phase 2 clinical trials of its NeoCart autologous tissue implant and is currently in a Phase 3 IND clinical study. Based in Waltham, Massachusetts, the company is privately held. For more information, visit http://www.histogenics.com.

See the article here:
Histogenics to Present at 7th Annual New York Stem Cell Summit

World Stem Cells, LLC Stem Cell Therapy at a state of the art clinic in beautiful Cancun. The clinic is staffed by top specialist in the field of stem cell implants and a new laboratory to support the stem cell treatments given.

(PRWEB) February 16, 2012

World Stem Cells, LLC. contract laboratory Advanced Cellular Engineering Lab (Ingenieria Celular Advanzada S.A. de C.V.) a new adult stem cell laboratory being built in Cancun, Mexico to support Stem Cell research, stem cell clinical trials and stem cell treatments. This was accomplished by private funding in conjunction with World Stem Cells, LLC worldstemcells.com a US patient management company, Medicina Biocelular Avanzada , S.E. de C.V. a Mexican patient management company and Advanced Cellular Medicine Clinic of Cancun, a Stem Cell treatment Clinic owned and operated by Dr. Sylvia M. Abblitt a well known board certified hematologist and oncologist, in Cancun.

Uniquely, Dr. Abblitt is one of a limited number of physicians licensed to perform autologous and allogeneic stem cell transplants. Dr. Abblitt has been utilizing stem cell therapies with successes for many years.

She is the president and lab director of Advanced Cellular Engineering Lab (Ingenieria Celular Advanzada S.A. de C.V.). Her extensive background includes having been the laboratory director and head of hematology for Hospital Fernando Quiroz for 11 years. As a pioneer in the stem cell transplant field, she brings a vast array of knowledge to the lab. Her memberships include the american association of blood banks (aabb), Mexican society of transfusional medicine, interamerica society of transfusional medicine, Mexican association) for studies of hematologyandicms and ICMS (international cellular medical society and all patients are monitored by ICMS an independent agency for a period of between 2-20 years on a quarterly basis. Dr. abblitt has had a 26-year clinical practice history.

The laboratory construction is complete and operations were transferred to our new facility. This facility provides Cancun, and patient around the world, a state of the art GLP laboratory to support their stem cell treatments in a beautiful, and positive environment. The lab was designed and constructed to provide one ISO7 lab, one wet lab along with a treatment area. This will allow stem cell retrieval, testing, culturing, selection, counting, analyses and sorting along with cryopreservation, without removal from the lab. This all in house capability reduces the possibility of contamination and errors. Dr. M. Abblitt will operate the Lab under cGMP/cGLP guidelines and use the state of the art facility to provide quality care to her stem cell transplant patients.

Working under the guidelines set forth by ICMS world stem cells, LLC ( http://worldstemcells.com/ ) provides stem cell treatment for ankylosing spondylitis, autism, cerebral palsy, charcot-marie-tooth disease (cmt), crohn’s diseases, copd, fuch’s disease, guillain-barre’ syndrome, hashimoto’s thryroiditis, itp, kidney diseases, macular degeneration, lupus (sle), multiple sclerosis, pad, parkinson’s disease, rheumatoid arthritis, scleroderma, stroke, ulcerative colitis

The laboratory will be engaged in private clinical trials, IRB’s and joint studies with US companies, Mexican Educational Institutes, US universities and doctors to better understand the benefits and precaution to be taken in the stem cell treatment process.

###

Charles Newcomer

727-421-4359
Email Information

See the article here:
World Stem Cells, LLC. Stem Cell Treatments In Cancun at Advanced Cellular Medicine Clinic

Line is first from U-M accepted to the U.S. National Institutes of Health registry, now available for federally-funded research

ANN ARBOR, Mich., Feb. 14, 2012 /PRNewswire-USNewswire/ -- The University of Michigan's first human embryonic stem cell line will be placed on the U.S. National Institutes of Health's registry, making the cells available for federally-funded research. It is the first of the stem cell lines derived at the University of Michigan to be placed on the registry.

The line, known as UM4-6, is a genetically normal line, derived in October 2010 from a cluster of about 30 cells removed from a donated five-day-old embryo roughly the size of the period at the end of this sentence. That embryo was created for reproduction but was no longer needed for that purpose and was therefore about to be discarded.

"This is significant, because acceptance of these cells on the registry demonstrates our attention to details of proper oversight, consenting, and following of NIH guidelines established in 2009," says Gary Smith, Ph.D., who derived the line and also is co-director of the U-M Consortium for Stem Cell Therapies, part of the A. Alfred Taubman Medical Research Institute.

"It now makes the line available to researchers who can apply for federal funding to use it in their work; this is an important step."

The line is the culmination of years of planning and preparation and was made possible by Michigan voters' November 2008 approval of a state constitutional amendment permitting scientists here to derive embryonic stem cell lines using surplus embryos from fertility clinics or embryos with genetic abnormalities and not suitable for implantation.

"We expect these cells will be used by investigators worldwide to enhance our understanding of stem cell biology, and together with disease-specific lines, discover treatments and cures for genetic diseases," says Smith, who is a professor in the Department of Obstetrics and Gynecology at the University of Michigan Medical School.

U-M is among just a handful of U.S. universities creating human embryonic stem cell lines. There are only 147 stem cell lines available on the registry.

"We envision in the future that investigators will be able to use the genetically normal embryonic stem cell lines like UM4-6, together with disease-specific embryonic stem cell lines, as a model system to investigate what causes these diseases and come up with treatments," says Sue O'Shea, professor of Cell and Developmental Biology, and co-director of the Consortium for Stem Cell Therapies.

U-M also has two other human embryonic stem cells lines submitted to the national registry. Both are disease specific, the first carrying the genetic defect that causes hemophilia B, and the other carries the gene responsible for Charcot-Marie-Tooth disease, a hereditary neurological disorder.

Smith expects to soon submit eight additional human embryonic stem lines for consideration on the national registry: three genetically normal and five new disease specific lines.

This is a historic achievement that will lead to treatments and cures for serious, life-altering diseases and is more evidence that our University of Michigan researchers are leading the world in cutting-edge science that will impact health around the globe, says Eva Feldman, M.D., Ph.D., director of the A. Alfred Taubman Medical Research Institute.

"This is another major step forward for medical science in Michigan. This opens us another avenue for researchers to really begin exploring the causes and progression of those diseases, with the ultimate goal of finding new therapies for patients," says Feldman.

Contributors to the A. Alfred Taubman Medical Research Institute's Consortium for Stem Cell Therapies include the Taubman Institute; the Office of the Executive Vice President for Medical Affairs; the Office of the Medical School Dean; the Comprehensive Cancer Center; the Department of Pediatrics and Communicable Diseases; the Office of the Vice President for Research; the School of Dentistry; the Department of Pathology; the Department of Cell and Developmental Biology; the College of Engineering; the Life Sciences Institute; the Department of Neurology; and U-M's Michigan Institute for Clinical and Health Research.

A. Alfred Taubman, founder and chair of U-M's Taubman Institute, called the registry placement a tremendous step for stem cell research.

"I consider stem cells to be a modern medical miracle – the most exciting advance in medicine since antibiotics. The progress we have made throughout the state in stem cell research has been nothing short of remarkable," says Taubman.

"This milestone means much to the University of Michigan and the state of Michigan, but also to the world. It offers another route for researchers to move ahead in studying these horrible diseases. We hope it is the first of many lines that the University of Michigan can contribute to the global efforts to improve human health."

For more information about the A. Alfred Taubman Medical Research Institute at the University of Michigan Medical School, visit http://www.taubmaninstitute.org

For more information about stem cell research at U-M, visit http://www.umich.edu/stemcell

SOURCE University of Michigan Health System

Back to top

RELATED LINKS
http://www.med.umich.edu

Link:
U-M Human Embryonic Stem Cell Line Placed On National Registry for Researchers

Dentists can be at the forefront of the emerging field of regenerative medicine by offering Store-A-Tooth™ dental stem cell banking.

This service enables families to save their own adult stem cells from teeth that are naturally coming out or being extracted. Dental professionals play a role in making patients aware of this option, giving families the choice to safely and securely store their stem cells today – in a convenient and affordable way – so that they can take advantage of future therapies in regenerative medicine and dentistry.

Provia Laboratories, LLC will be exhibiting its Store-A-Tooth™ dental stem cell preservation service during the Chicago Midwinter Meeting at booth # 3346.

Lexington, MA (PRWEB) February 15, 2012

Provia Laboratories, LLC will be exhibiting during the Chicago Midwinter Meeting at booth # 3346 to showcase its Store-A-Tooth™ dental stem cell preservation service.

The Store-A-Tooth service enables families to save their own adult stem cells – from baby teeth ready to fall out; teeth pulled for orthodontic reasons; and wisdom teeth being extracted. Dental professionals play a role in making patients aware of this option, giving families the choice to safely and securely store their stem cells today – in a convenient and affordable way – so that they can take advantage of future therapies in regenerative medicine and dentistry.

The company partners with dental offices to make it easy to educate and inform patients about the option to preserve their family’s dental stem cells. For those interested in the service, Provia works with the dental team to provide high quality tooth collection, and arranges for the sample to be sent overnight to the lab, where the stem cells are harvested, tested and cryopreserved for future potential use.

“New stem cell therapies are going to change medicine as we know it, and dentists will play a leading role in enabling this transformation,” states Howard Greenman, Provia Labs CEO. “There’s been a lot of media buzz about stem cell research in general, but most people are unaware that a very potent and plentiful source of viable stem cells exits in the dental pulp of healthy teeth.”

Dental stem cells have already successfully been used in people to regenerate alveolar jaw bone and to treat periodontal disease. “One of the first routine applications in the oral cavity for the use of mesenchymal stem cells from teeth will be to promote bone growth around implants so they integrate more quickly, similar to how cellular bone matrix products are used today,” says Dr. Nicholas Perrotta, DMD, who started providing the Store-A-Tooth service in 2011.

“In addition to potential applications in regenerative dentistry, dental stem cell research may lead to new treatments for a wide range of medical conditions, including type 1 diabetes, stroke, cardiovascular disease, spinal cord injuries, and Parkinson’s disease, to name a few,” explains Peter Verlander, PhD, Chief Scientific Officer for Provia Labs. “Dental stem cell collection and preservation gives parents the peace of mind that they are now equipped to take advantage of the breakthroughs in stem cell therapies that will arise from the research community.”

“Store-A-Tooth is less expensive than collecting stem cells from umbilical cord blood. In fact, we hear from many of our customers that they are thankful to have this opportunity to store their stem cells, especially if they missed the chance to save cord blood,” states Greenman. “Our mission is to make stem cell banking accessible to the millions of children losing teeth every year.”

There are no fees or costs to dentists who wish to become an authorized Store-A-Tooth provider; in fact dentists can generate incremental revenue for assisting with tooth collection. Provia Labs supplies all participating practices with patient education materials, practice tools and dedicated support; training is simple and there is minimal impact to existing workflow.

Dental professionals share Store-A-Tooth educational materials with their patients, who enroll directly with Provia Labs. The day of the appointment, the dentist simply places the extracted tooth into the Store-A-Tooth collection kit, which includes a proven transport device called Save-A-Tooth®. In use by thousands of dentists for over 20 years, the Save-A-Tooth is an FDA-approved and ADA-accepted device for transporting avulsed teeth for reimplantation. The Store-A-Tooth collection kit is shipped overnight to the Provia Laboratories facility, where the stem cells are processed and stored.

The Store-A-Tooth service is currently available to dental offices throughout the United States and internationally. To become a provider, visit http://www.store-a-tooth.com or call 877-867-5753.

About Provia Laboratories, LLC

Headquartered in Lexington, MA, Provia Laboratories, LLC (http://www.provialabs.com) is a healthcare services company specializing in high quality biobanking (preservation of biological specimens). The company’s Store-A-Tooth™ service platform enables the collection, transport, processing, and storage of dental stem cells for potential use in future stem-cell therapies. The company advises industrial, academic, and governmental clients on matters related to the preservation of biological specimens for research and clinical use. In addition, Provia offers a variety of products for use in complex biobanking environments to improve sample logistics, security, and quality. For more information on dental stem cells, call 1-877-867-5753, visit http://www.store-a-tooth.com or http://www.facebook.com/storeatooth, or follow via twitter @StoreATooth.

###

Store-A-Tooth
Provia Laboratories, LLC
877-867-5753
Email Information

Read the original here:
Provia Labs Makes Chicago Midwinter Meeting Debut and Launches Store-A-Tooth™ Dental Stem Cell Preservation, Enabling ...

Yesterday the University announced it will contribute a line of human embryonic stem cells to the U.S. National Institutes of Health registry as part of a continuing effort to develop treatments for life-threatening diseases.

For the past two weeks, the University has been finalizing plans to make the line available nationally. This will be the University’s first national addition to the registry since Michigan voters approved a constitutional amendment allowing research on surplus embryos unfit for reproduction in 2008. Other universities, including the University of California, Los Angeles, Stanford University and the University of Connecticut, have also contributed to the registry.

The NIH registry created guidelines in July 2009 that make independently generated embryonic lines for federally funded research available. There are currently 147 stem cell lines on the registry.

Gary Smith, co-director of the A. A. Taubman Consortium for Stem Cell Therapies, started work on the line in October 2010. Smith said development of the line sets the University apart from other major research institutes.

“I do believe it makes us unique in comparison to many other universities,” Smith said. “It does put us in a handful of universities across the Unites States (that have contributed to the registry).”

The line was created from a five-day-old embryo approximately the size of a period, which would have been discarded because it was not fit for implantation. The cells will be used to understand stem cell biology, how certain diseases form and to design treatments and cures for those diseases, Smith said.

The line is genetically normal, but University researchers are working to develop two disease-specific lines, Smith said. Researchers are also working on eight others — five of which will be genetically normal.

Sue O’Shea, the other co-director of the Consortium, said in a press release the combination of the two types of stem cell lines will open up a wide range of possibilities in disease research.

“We envision in the future that investigators will be able to use the genetically normal embryonic stem cell lines … together with disease-specific embryonic stem cell lines, as a model system to investigate what causes these diseases and come up with treatments,” O’Shea said.

Eva Feldman, director of the A.A. Taubman Medical Research Institute, said in the press release the breakthrough of the developing lines offers additional opportunities to find cures to diseases.

“This is another major step forward for medical science in Michigan,” Feldman said. “This opens up another avenue for researchers to really begin exploring the causes and progression of those diseases, with the ultimate goal of finding new therapies for patients.”

A. Alfred Taubman, founder and chair of the Taubman Institute, added in the press release that the recent stem cell progress is monumental for the University’s research programs.

“I consider stem cells to be a modern miracle — the most exciting advance in medicine since antibiotics,” Taubman said. “The progress we have made throughout the state in stem cell research has been nothing short of remarkable.”

Read the original:
‘U’ stem cell line added to NIH

ANN ARBOR — The University of Michigan’s first human embryonic stem cell line will be placed on the U.S. National Institutes of Health’s registry, making the cells available for federally funded research. It is the first of the stem cell lines derived at the University of Michigan to be placed on the registry.

The line, known as UM4-6, is a genetically normal line, derived in October 2010 from a cluster of about 30 cells removed from a donated five-day-old embryo roughly the size of the period at the end of this sentence. That embryo was created for reproduction through in-vitro fertilization but was no longer needed for that purpose and was therefore about to be discarded.

“This is significant, because acceptance of these cells on the registry demonstrates our attention to details of proper oversight, consenting, and following of NIH guidelines established in 2009,” says Gary Smith, who derived the line and also is co-director of the U-M Consortium for Stem Cell Therapies, part of the A. Alfred Taubman Medical Research Institute. “It now makes the line available to researchers who can apply for federal funding to use it in their work; this is an important step.”

The line is the culmination of years of planning and preparation and was made possible by Michigan voters’ November 2008 approval of a state constitutional amendment permitting scientists here to derive embryonic stem cell lines using surplus embryos from fertility clinics or embryos with genetic abnormalities and not suitable for implantation.

“We expect these cells will be used by investigators worldwide to enhance our understanding of stem cell biology, and together with disease-specific lines, discover treatments and cures for genetic diseases,” says Smith, who is a professor in the Department of Obstetrics and Gynecology at the University of Michigan Medical School.

UM is among just a handful of United States universities creating human embryonic stem cell lines. There are only 147 stem cell lines available on the registry.

“We envision in the future that investigators will be able to use the genetically normal embryonic stem cell lines like UM4-6, together with disease-specific embryonic stem cell lines, as a model system to investigate what causes these diseases and come up with treatments,” said Sue O’Shea, professor of Cell and Developmental Biology, and co-director of the Consortium for Stem Cell Therapies.

UM also has two other human embryonic stem cells lines submitted to the national registry. Both are disease specific, the first carrying the genetic defect that causes hemophilia B, and the other carries the gene responsible for Charcot-Marie-Tooth disease, a hereditary neurological disorder.

Smith expects to soon submit eight additional human embryonic stem lines for consideration on the national registry: three genetically normal and five new disease specific lines.

This is a historic achievement that will lead to treatments and cures for serious, life-altering diseases and is more evidence that our University of Michigan researchers are leading the world in cutting-edge science that will impact health around the globe, says Eva Feldman, M.D., director of the A. Alfred Taubman Medical Research Institute.

“This is another major step forward for medical science in Michigan,” Feldman said. “This opens us another avenue for researchers to really begin exploring the causes and progression of those diseases, with the ultimate goal of finding new therapies for patients.”

Contributors to the A. Alfred Taubman Medical Research Institute’s Consortium for Stem Cell Therapies include the Taubman Institute; the Office of the Executive Vice President for Medical Affairs; the Office of the Medical School Dean; the Comprehensive Cancer Center; the Department of Pediatrics and Communicable Diseases; the Office of the Vice President for Research; the School of Dentistry; the Department of Pathology; the Department of Cell and Developmental Biology; the College of Engineering; the Life Sciences Institute; the Department of Neurology; and U-M’s Michigan Institute for Clinical and Health Research.

A. Alfred Taubman, founder and chair of UM’s Taubman Institute, called the registry placement a tremendous step for stem cell research.

“I consider stem cells to be a modern medical miracle – the most exciting advance in medicine since antibiotics. The progress we have made throughout the state in stem cell research has been nothing short of remarkable,” Taubman said. “This milestone means much to the University of Michigan and the state of Michigan, but also to the world. It offers another route for researchers to move ahead in studying these horrible diseases. We hope it is the first of many lines that the University of Michigan can contribute to the global efforts to improve human health.”

For more information about the A. Alfred Taubman Medical Research Institute at the University of Michigan Medical School, visit http://www.taubmaninstitute.org

See the original post here:
UM Human Embryonic Stem Cell Line Placed On National Registry